BeiGene, Ltd. (BEIGF)
OTCMKTS
· Delayed Price · Currency is USD
15.50
0.00 (0.00%)
At close: Nov 11, 2024
BeiGene Revenue
BeiGene had revenue of 7.35B CNY in the quarter ending September 30, 2024, with 39.54% growth. This brings the company's revenue in the last twelve months to 23.51B, up 50.22% year-over-year. In the year 2023, BeiGene had annual revenue of 2.46B with 73.65% growth.
Revenue (ttm)
23.51B CNY
Revenue Growth
+50.22%
P/S Ratio
n/a
Revenue / Employee
2.22M CNY
Employees
10,600
Market Cap
20.64B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |